The value-based agreement concerns Merck’s type 2 diabetes treatments, Januvia and Janumet. Under the agreement, Merck’s rebates for the drugs will in part be determined by the drugs’ achievement of treatment goals for Aetna commercial plan members with type 2 diabetes.
The Kenilworth, N.J.-based pharmaceutical company is also the first healthcare company to partner with the Hartford, Conn.-based insurer for its AetnaCare plan. The initiative uses predictive analytics to target populations that would benefit from specific health and wellness services.
AetnaCare will initially identify diabetes and hypertension patients in mid-Atlantic markets. Merck will provide educational resources about patient engagement, behavior and treatment adherence as part of the collaboration.
More articles about payer issues:
Why CMS called this NYT headline ‘100% wrong and irresponsible’
UnitedHealthcare gives DOJ ‘highly confidential’ data for Aetna-Humana, Anthem-Cigna suits
DOJ lawyers claim Aetna, Humana attorneys are trying to ‘derail’ antitrust case
